PMID- 32000913
OWN - NLM
STAT- MEDLINE
DCOM- 20201218
LR  - 20201218
IS  - 1557-7988 (Electronic)
IS  - 0076-6879 (Linking)
VI  - 632
DP  - 2020
TI  - Recombinant fusion proteins for targeting dendritic cell subsets in therapeutic 
      cancer vaccine.
PG  - 521-543
LID - S0076-6879(19)30470-7 [pii]
LID - 10.1016/bs.mie.2019.11.013 [doi]
AB  - Dendritic cells (DCs) are professional antigen-presenting cells, which are 
      optimal for the priming of a T cell response against pathogens and tumors. 
      Therefore, many efforts are made to develop therapeutic cancer vaccines which 
      preferentially target the antigen to DC subsets. To this aim, we developed two 
      types of recombinant fusion proteins, which favor antigen delivery to 
      pro-inflammatory DCs as well as the crosstalk between specialized subpopulations 
      of DCs. The first approach combines peptide/CpG vaccination with the recruitment 
      of iNKT cells to the tumor site via CD1d-antitumor scFv fusion proteins. The 
      second approach is targeting the tumor antigen to cross-presenting Xcr1(+) DCs 
      via a fusion protein made of Xcl1 fused to a synthetic long peptide followed by 
      an IgG1 Fc fragment. Both strategies allow a potent tumor-specific CD8 T cell 
      response associated with tumor regression or tumor growth delay depending on the 
      model. In the case of iNKT cell activation, the strategy relies on a strong IL-12 
      release by splenic DCs, while in the second case, the T cell response is strictly 
      dependent on the presence of Xcr1(+) cross-presenting DCs.
CI  - (c) 2020 Elsevier Inc. All rights reserved.
FAU - Corgnac, Stephanie
AU  - Corgnac S
AD  - Department of Fundamental Oncology, Faculty of Biology and Medicine, University 
      of Lausanne, Epalinges, Switzerland; INSERM UMR 1186, Integrative Tumor 
      Immunology and Genetic Oncology, Gustave Roussy, EPHE, PSL, Fac. de 
      Medecine-Univ. Paris-Sud, Universite Paris-Saclay, Villejuif, France.
FAU - Botelho, Natalia K
AU  - Botelho NK
AD  - Department of Fundamental Oncology, Faculty of Biology and Medicine, University 
      of Lausanne, Epalinges, Switzerland.
FAU - Donda, Alena
AU  - Donda A
AD  - Department of Fundamental Oncology, Faculty of Biology and Medicine, University 
      of Lausanne, Epalinges, Switzerland. Electronic address: alena.donda@unil.ch.
FAU - Romero, Pedro
AU  - Romero P
AD  - Department of Fundamental Oncology, Faculty of Biology and Medicine, University 
      of Lausanne, Epalinges, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20191218
PL  - United States
TA  - Methods Enzymol
JT  - Methods in enzymology
JID - 0212271
RN  - 0 (Cancer Vaccines)
RN  - 0 (Recombinant Fusion Proteins)
SB  - IM
MH  - Animals
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - Cross-Priming
MH  - Dendritic Cells/*immunology
MH  - HEK293 Cells
MH  - Humans
MH  - Killer Cells, Natural/immunology
MH  - Mice, Inbred C57BL
MH  - Neoplasms/immunology/*therapy
MH  - Recombinant Fusion Proteins/immunology/therapeutic use
OTO - NOTNLM
OT  - CD1d
OT  - CD8+ T cell
OT  - Cross-presenting DC
OT  - Recombinant fusion protein
OT  - Tumor vaccine
OT  - Xcl1
OT  - Xcr1+ DC
OT  - iNKT cell
EDAT- 2020/02/01 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/02/01 06:00
PHST- 2020/02/01 06:00 [entrez]
PHST- 2020/02/01 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
AID - S0076-6879(19)30470-7 [pii]
AID - 10.1016/bs.mie.2019.11.013 [doi]
PST - ppublish
SO  - Methods Enzymol. 2020;632:521-543. doi: 10.1016/bs.mie.2019.11.013. Epub 2019 Dec 
      18.